Sigma-Aldrich Corporation Logo


Committee Composition

Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member
  Audit Corporate Governance Compensation Science & Technology
Rebecca M. Bergman Member of Audit Committee     Member of Science & Technology Committee
Rebecca Bergman Vice President, New Therapies & Diagnostics, Cardiac Rhythm Disease Management, Medtronic, Inc.

Ms. Bergman has more than 22 years of experience in the medical technology industry including over 15 years of experience in research and technology management and product development. Since February 2009, she has served as Vice President, New Therapies and Diagnostics for Cardiac Rhythm Disease Management of Medtronic, Inc., a manufacturer of products and therapies used in the diagnosis, treatment and monitoring of chronic medical conditions. She previously served as Vice President, Science and Technology of Medtronic, Inc. from April 2002 to February 2009. Ms. Bergman has been a director of the Company since 2008. She serves as a member of the National Advisory Committee of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the NIH and on a number of academic advisory boards. Ms. Bergman is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and was elected as a member of the National Academy of Engineering (NAE) in February 2010. Age 56.


George M. Church, Ph. D.   Member of Corporate Governance Committee   Member of Science & Technology Committee
Professor of Genetics at the Harvard Medical School and Director of the Center for Computational Genetics in Cambridge, Massachusetts.

Dr. Church is a Professor of Genetics at the Harvard Medical School and Director of the Center for Computational Genetics in Cambridge, Massachusetts. Dr. Church pioneered technology innovations early in the development of key fields in Chemistry and Biomedicine with over 10 U.S. patents granted and several pending. His work in the first direct Genomic Sequencing and Molecular Multiplexing technology has resulted in a new paradigm in biological research. Age 58.


Michael L. Marberry Member of Audit Committee   Member of Compensation Committee  
President and CEO
J.M. Huber Corporation

Mr. Marberry has more than 30 years of management experience, including more than 16 years with J.M. Huber Corporation, a company that provides products in the fields of engineering, natural resources and technology.    He has served as President and Chief Executive Officer since 2009.  Mr. Marberry served as President, Huber Engineered Materials from 2006 to 2009, Chief Financial Officer from 2002 to 2006, and Managing Director, Chairman of the Board of Management and Corporate Vice President for New Business Development with Noviant Group, a subsidiary of J.M. Huber from 1997 to 2002.   Prior to joining J.M. Huber, Mr. Marberry served in senior roles at M.A. Hanna Company, an iron ore processing company in Cleveland, Ohio and served in various roles with McKinsey & Company, Inc. and The Proctor and Gamble Company.    He has been a director of the Company since 2012.  Mr. Marberry earned his Masters in Business Administration degree from Amos Tuck School of Business Administration at Dartmouth College and his Masters of Science and Bachelor of Science in Chemical Engineering at the University of Kentucky.  Age 54.



 


W. Lee McCollum Member of Audit Committee Member of Corporate Governance Committee    
W. Lee McCollum Former Executive Vice President & Chief Financial Officer
S.C. Johnson & Son, Inc.

Mr. McCollum is an audit committee financial expert and has significant management experience including more than 35 years of experience with S.C. Johnson and Son, Inc., a global manufacturer and marketer of consumer products, where he held positions involving accounting, treasury, taxes, internal audit, mergers and acquisitions, strategic planning, personnel matters, international operations and general management. At S.C. Johnson and Son., Inc., he served as Senior Vice President and Chief Financial Officer from 1997 to 2004 and as Executive Vice President and Chief Financial Officer from 2005 to 2009. From 2005 to 2009, his responsibilities also included global manufacturing. Mr. McCollum has been a director of the Company since 2001. He is also a director of Johnson Outdoors, Inc., and serves as Vice Chairman and director of Johnson Financial Group, a large private regional bank holding company. Age 63.


Avi M. Nash Committee Chair for Audit Committee   Member of Compensation Committee  
Managing Director of Avi Nash LLC (Former partner of Goldman Sachs)

Avi M. Nash Managing Director of Avi Nash LLC, a management consulting firm in Greenwich, Connecticut, that works with global chemical industry leaders in mergers and acquisitions, capital market transactions and other strategic matters. Prior to launching his firm in 2003, he was a partner at Goldman Sachs, New York, New York, for more than five years. He has been a director of the Company since November 2005. Age 60.


Steven M. Paul, M.D.     Member of Compensation Committee Committee Chair for Science & Technology Committee
Director of the Appel Alzheimer's Disease Research Institute and Professor of Neurology, Psychiatry and Pharmacology at Weill Cornell Medical College

Steven M. Paul, M.D., is the Director of the Helen and Robert Appel Alzheimer’s Disease Research Institute and Professor of Neurology (Neuroscience) and Psychiatry at Weill Cornell Medical College. He was formerly the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories, a division of Eli Lilly and Company. Prior to assuming his position at Lilly, Paul served as Scientific Director of the National Institute of Mental Health (NIMH/NIH) in Bethesda, Maryland.  He has been a director of the Company since November 2006. He currently serves on the Scientific Advisory Boards of the Allen Institute for Brain Science and the Institute on Aging at the University of Pennsylvania School of Medicine. He is also a director of the Foundation of the NIH. Age 62.


J. Pedro Reinhard   Committee Chair for Corporate Governance Committee Member of Compensation Committee  
J. Pedro Reinhard President of Reinhard & Associates (Former CFO, Dow Chemical Company)

Mr. Reinhard has more than 35 years of experience in the chemicals industry and more than 30 years of international management experience, including more than 10 years as a chief financial officer. He is an audit committee financial expert and has significant capital markets and finance experience. Mr. Reinhard served as Executive Vice President and Chief Financial Officer of The Dow Chemical Company ("Dow"), a manufacturer of chemicals, plastic materials, agricultural and other specialized products, Midland, Michigan, from 1995 to 2005. Previously, Mr. Reinhard held a variety of senior international, financial and operating leadership positions at Dow after beginning his career there in 1970 in Brazil and other senior operations assignments in Europe. In 1988, Mr. Reinhard was appointed Treasurer of Dow. Mr. Reinhard served as a director of Dow from 1995 to 2007. He presently serves as President of Reinhard & Associates, a financial advisory practice since 2006. He has been a director of the Company since 2001. He is also a director of Colgate Palmolive Co. and Royal Bank of Canada. Age. 67.


Rakesh Sachdev        
President and CEO

Rakesh was elected in November 2010. Rakesh is the President and CEO of Sigma-Aldrich. Prior to that he served as Senior Vice President and Chief Financial and Administrative Officer of Sigma-Aldrich Corporation. Mr. Sachdev joined the company in November 2008. Prior to joining the company, he served as Senior Vice President and President, Asia Pacific at ArvinMeritor, Inc. where he also held numerous other leadership positions in finance, strategy and general management since 1999. Previously, he was with Cummins, Inc. where he started in 1981 and was Chief Financial Officer, Automotive Business Unit, and held various other positions over many years. He was elected a Director of the Company in November, 2010.


D. Dean Spatz   Member of Corporate Governance Committee Committee Chair for Compensation Committee  
Former Chairman and CEO, Osmonics, Inc.

D. Dean Spatz CEO of Watasso Ventures, a company that specializes in investing in and actively participating in the management and development of entrepreneurial start-up companies. Former Chairman and Chief Executive Officer of Osmonics, Inc., a manufacturer of water purification, fluid separation and fluid handling products and equipment, Minnetonka, Minnesota. He was founder, Chairman and Chief Executive Officer of Osmonics, Inc. for more than five years until February 2003 when Osmonics, Inc. was acquired by GE Infrastructure, a unit of General Electric Company. He has been a director of the Company since 1994. He also serves as a director of three privately held companies. Age 68.


Barrett Toan Chairman of the Board   Member of Corporate Governance Committee    
Barrett Toan Former Chairman and CEO of Express Scripts, Inc.

Barrett A. Toan Former Chairman of Express Scripts, Inc., a pharmacy benefits management company, St. Louis, Missouri. He was Chairman of Express Scripts, Inc. for more than five years until May 2006. He also served as Chief Executive Officer of Express Scripts, Inc. for more than five years until March 2005. He has been a director of the Company since 2001. He is also a director of Express Scripts, Inc. and Genworth Financial, Inc. Age 65.